Korro Bio, Inc. (KRRO)

Korro Bio's stock has been significantly impacted by several events in the past six months. In November 2025, the stock price dropped by approximately 80% after KRRO-110 failed in a Phase 1/2a trial, leading to layoffs, the resignation of its chief medical officer, and a pause in its partnership with Novo Nordisk. The company reported its third-quarter 2025 financial results on November 12, 2025, and recorded its 52-week low of $5.20 on December 1, 2025. On March 12, 2026, Korro Bio reported its fourth-quarter and full-year 2025 financial results. On March 31, 2026, Lynx1 Capital Management L.P. purchased 520 shares of the company's common stock. As of April 2, 2026, the stock price was $14.00 per share, with a 57.93% year-to-date gain. On April 10, 2026, Korro Bio announced an inducement grant under Nasdaq Listing Rule 5635(c)(4) and raised $85 million through a private equity financing round led by Venrock Healthcare Capital Partners. Analyst firms have upgraded the stock or increased their price targets, reflecting renewed confidence in the company's focus on hyperammonemia indications and its KRRO-121 program. The stock has exhibited significant volatility, with a beta of 2.54.

The demand for Korro Bio's products and services is not subject to typical seasonal fluctuations. Demand is primarily driven by the prevalence of the diseases it aims to treat and the progress and success of its clinical development programs.

Korro Bio, Inc. is a biopharmaceutical company focused on developing genetic medicines through RNA editing, offering increased precision, tunability, specificity, and improved long-term tolerability for treating diseases. Its proprietary platform is called Oligonucleotide Promoted Editing of RNA (OPERA®). The company's lead product candidate is KRRO-121, for the treatment of hyperammonemia, including urea cycle disorders (UCD) and hepatic encephalopathy (HE). Korro Bio is also exploring programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Previously, KRRO-110 failed to meet projected protein levels in a Phase 1/2a trial, leading the company to pivot its AATD program to a different delivery method.

Korro Bio, Inc. is headquartered in Cambridge, Massachusetts, United States, with its operations and focus primarily within the United States.

Korro Bio's brand reputation has been affected by both challenges and renewed optimism. The failure of KRRO-110 and subsequent layoffs likely had a negative impact, but the company's strategic pivot, successful financing, and recent analyst upgrades suggest a potential recovery. MarketBeat's evaluation indicates that Korro Bio scored higher than 64% of companies in the medical sector, and analysts currently hold a "Moderate Buy" consensus rating for the company.

Korro Bio, Inc. has a substantial number of institutional owners and shareholders. As of April 10, 2026, there were 88 institutional owners holding a total of 7,514,400 shares, including Atlas Venture Life Science Advisors, LLC, NEA Management Company, LLC, Lynx1 Capital Management LP, and Vanguard Group Inc. Among individual owners, Anthony Jr. Florence acquired 207,100 shares in March 2026.